Liscastobart clinical trials
Also written BAT1308.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2020
How each study uses liscastobart is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2024 (2)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2022 | 1 |
| 2024 | 2 |
Who runs them
Industry 4 · Other 0
Often tested with
Tested in the same studies.
Anti-TROP2 Antibody-drug Conjugate BAT8008 (1) · BAT4706 (1) · Vedastotug (1)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test liscastobart.
Studies
Open first, then newest update. How each study uses liscastobart is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Assessment of Safety, Tolerability and Pharmacokinetics With BAT4706 and BAT1308 in Advanced Solid Tumors PatientsCompletedPhase 1Bio-Thera SolutionsNCT06139536Written as BAT1308 Injection
- A Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of the Combination of BAT8008 With BAT1308 in Patients With Advanced Solid TumorsActive, not recruitingPhase 1/2Bio-Thera SolutionsNCT06341114Written as BAT1308 injection
- Assessment of Safety ,Tolerance and Pharmacokinetics Clinical Efficacy With BAT1308 in Advanced Solid TumorsCompletedPhase 1Bio-Thera SolutionsNCT05155722Written as BAT1308
- Assessment of Safety and Preliminary Efficacy With BAT6026 in Solid Tumour PatientsTerminatedPhase 1Bio-Thera SolutionsNCT05109650Written as BAT1308
Given beside what is tested · 1 — liscastobart is usual care or a partner of the new treatment
Codes
What other systems call liscastobart · ClinicalTrials.gg INT018263
- UNII (FDA) VNS9LT4XDBLISCASTOBARTOne source FDA
- NCI Thesaurus C185390LiscastobartOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | VNS9LT4XDB | LISCASTOBART | One source FDA |
| NCI Thesaurus | C185390 | Liscastobart | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.